Menopause-related medication use among women age 45-75 experiencing incarceration in North Carolina 2015-2016

DOIhttps://doi.org/10.1108/IJPH-07-2021-0068
Published date27 January 2022
Date27 January 2022
Pages176-184
Subject MatterHealth & social care,Criminology & forensic psychology,Prisoner health,Sociology,Sociology of crime & law,Public policy & environmental management,Policing,Criminal justice
AuthorElana Jaffe,David Rosen,Aunchalee Palmquist,Andrea K. Knittel
Menopause-related medication use
among women age 45-75 experiencing
incarceration in North Carolina 2015-2016
Elana Jaffe, David Rosen, Aunchalee Palmquist and Andrea K. Knittel
Abstract
Purpose This study aims to estimate the prevalence of individuals receiving hormone therapy for
menopause management and the prevalence of underlying conditions that may constrain options for
pharmacologicmenopause management inthe prison context.
Design/methodology/approach This study reviewed all prescriptions dispensed by the North
Carolina Department of Public Safety between July 1, 2015, and June 30, 2016, for relevance
to menopause management. Relevant medications were those either recommended for menopause
management or those indicated for management of conditions that may complicate menopause
management, as per the 2015clinical decision-support algorithm tool developedby the North American
MenopauseSociety. Analysis was restrictedto women between the ages of 45 and 75.
Findings Of 1,120 women, a majority(77.8%) were between the ages of 45 and 54. Less than 5% of
individuals in this study wereprescribed estrogen-containing therapy. The most commonly prescribed
medicationsthat may constrain options for menopause treatmentwere related to hypertension and other
cardiovasculardisease or mental health conditions.
Research limitations/implications The retrospective natureof this data set limits the findings, given
that researchers did not have access to diagnoses or data on polypharmacy. Still, this study indicates
that many women over 45 experiencing incarceration are living with health conditions that may
complicate menopause symptom management with hormone therapy. Future research in carceral
settings must examinethe prevalence of menopause-related symptomsas well as access to and quality
of comprehensivemenopause management.
Originality/value There is a paucity of literature around themenopause-related needs of individuals
experiencing incarceration. To the best of the authors’ knowledge, no other research has examined
prevalenceof pharmacologic menopause managementamong women who are incarcerated.
Keywords Women’s health, Health in prison, Aging, Incarceration, Menopause
Paper type Research paper
Introduction
The number of women 45 years of age experiencing incarceration in state or federal
prisons has more than doubled since 1999, with 25,337 women in this age group
incarcerated in 2019 (Beck, 2000;Carson, 2020). However, there is a lack of evidence
around the extent to whichmenopause-related health needs are being met in prison andjail
facilities (Schach et al., 2021). Though the experience of menopause varies between
women, many menopausal women report vasomotor symptoms (e.g. hot flashes),
urogenital symptoms (e.g. vaginal dryness), depression, sleep disruption, musculoskeletal
changes and hormonal changes. The average age of menopause is 51, though the median
duration of menopausal symptomsis just over 10 years, often starting years before the final
menstrual period (Kaunitz and Manson, 2015;de Kruif et al., 2016). Menopause symptoms
may be exacerbated for women in prison; social determinants of health prevalent among
(Informationabout the
authorscan be found at the
end of this article.)
Received 31 July 2021
Revised 14 December 2021
Accepted 3 January 2022
The authors acknowledge the
North Carolina Department of
Public Safety for their
assistance providing the data
used in this analysis.
Funding: This work was
supported in part by a
Community Engagement
Fellowship from the Carolina
Center for Public Service.
PAGE 176 jINTERNATIONAL JOURNAL OF PRISONER HEALTH jVOL. 18 NO. 2 2022, pp. 176-184, ©Emerald Publishing Limited, ISSN 1744-9200 DOI 10.1108/IJPH-07-2021-0068

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT